There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Paratek Pharmaceuticals (NASDAQ:PRTK), Epizyme (NASDAQ:EPZM) and Zynerba Pharmaceuticals (NASDAQ:ZYNE) with bullish sentiments.
Paratek Pharmaceuticals (PRTK)
In a report released today, Ed Arce from H.C. Wainwright maintained a Buy rating on Paratek Pharmaceuticals, with a price target of $55. The company’s shares closed on Friday at $9.80, close to its 52-week low of $9.38.
According to TipRanks.com, Arce is a 5-star analyst with an average return of 22.7% and a 41.5% success rate. Arce covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals Inc, Avenue Therapeutics Inc, and Conatus Pharmaceuticals.
Paratek Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $50, which is a 410.2% upside from current levels. In a report issued on August 2, Cantor Fitzgerald also maintained a Buy rating on the stock with a $50 price target.
.
See today’s analyst top recommended stocks >>
Epizyme (EPZM)
In a report released today, Jotin Marango from Roth Capital maintained a Buy rating on Epizyme, with a price target of $26. The company’s shares closed on Friday at $9.55, close to its 52-week low of $8.61.
Marango wrote:
“We disregard the optical fallout from DLBCL, and guide investors to stay focused on the timetable and potential in MUT-FL.”
According to TipRanks.com, Marango is a 4-star analyst with an average return of 16.0% and a 39.4% success rate. Marango covers the Healthcare sector, focusing on stocks such as KalVista Pharmaceuticals Inc, Stemline Therapeutics Inc, and Actinium Pharmaceuticals.
Epizyme has an analyst consensus of Strong Buy, with a price target consensus of $25, a 161.8% upside from current levels. In a report issued on August 2, Cowen & Co. also maintained a Buy rating on the stock.
.
Zynerba Pharmaceuticals (ZYNE)
In a report released today, Oren Livnat from H.C. Wainwright maintained a Buy rating on Zynerba Pharmaceuticals, with a price target of $23. The company’s shares closed on Friday at $5.59, close to its 52-week low of $5.42.
According to TipRanks.com, Livnat ‘s ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -9.7% and a 40.3% success rate. Livnat covers the Healthcare sector, focusing on stocks such as Pacira Pharmaceuticals, Jazz Pharmaceuticals, and Agile Therapeutics.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Zynerba Pharmaceuticals with a $19.33 average price target, representing a 245.8% upside. In a report issued on August 2, Cantor Fitzgerald also reiterated a Buy rating on the stock with a $20 price target.
.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
